TY  - JOUR
A1  - Klimek, Ludger
A1  - Lange, Lars
A1  - Blum, Lea Alexandra
A1  - Klimek, Felix
A1  - Nemat, Katja
A1  - Reese, Imke
A1  - Blümchen, Katharina
T1  - White paper on peanut allergy: treatment pathway
T2  - Allergo journal international
N2  - Background: Peanuts are a member of the legume family (botanical family Leguminosae) and peanut allergies are the most common cause of food anaphylaxis in many countries. The prevalence of peanut allergy is increasing.
Methods: Experts from Germany and Austria performed a standardized literature search and published their consensus recommendations in a White Paper on Peanut Allergy, which this care pathway is based upon, thus, providing a comprehensive diagnosis and treatment algorithm.
Results: The most important diagnostic key elements include a detailed clinical medical history, evidence of peanut-specific sensitization by means of skin prick testing and/or in vitro determination of the peanut (extract)-specific IgE and/or the molecular component diagnostics (most important Ara h 2-specific IgE, sometimes also Ara h1-, 3-, 6-, 8- and 9-specific IgE) as well as the gold standard, the double-blind, placebo-controlled food challenge. The diagnostic algorithms were created for the following constellations: Suspected primary peanut allergy with a clear history of systemic immediate-type reaction, suspected primary peanut allergy with questionable symptoms, suspected secondary (possibly pollen-associated) peanut allergy with a history of solely oropharyngeal symptoms and incidental finding of sensitization and no peanut ingestion so far.
Conclusions: After established diagnosis the standard of care is counseling to avoid peanut contact and prescription of emergency medications (oral antihistamines, oral steroids, inhaled β2-agonists, injectable intramuscular epinephrine) as needed. Instruction on the use of these emergency medications should be provided. A preparation for oral immunotherapy (OIT) for 4 to 17 years old peanut allergic children/ adolescents has been recently approved by the regulatory authorities. OIT for peanut allergy shows high efficacy and an acceptable safety profile, improves quality of life, and health economic aspects. Thus it offers a therapeutic option for peanut allergic children and adolescents.
KW  - Ara h2-specific IgE
KW  - Oral food challenge
KW  - Diagnostic algorithm
KW  - Oral immunotherapy (OIT)
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/69540
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-695406
SN  - 2197-0378
N1  - Open Access funding enabled and organized by Projekt DEAL.
VL  - 30
IS  - 8
SP  - 287
EP  - 289
PB  - Urban & Vogel
CY  - München
ER  -